Nothing Special   »   [go: up one dir, main page]

PE20141358A1 - Polimorfos de inhibidores de cinasas - Google Patents

Polimorfos de inhibidores de cinasas

Info

Publication number
PE20141358A1
PE20141358A1 PE2014000191A PE2014000191A PE20141358A1 PE 20141358 A1 PE20141358 A1 PE 20141358A1 PE 2014000191 A PE2014000191 A PE 2014000191A PE 2014000191 A PE2014000191 A PE 2014000191A PE 20141358 A1 PE20141358 A1 PE 20141358A1
Authority
PE
Peru
Prior art keywords
compound
formula
polymorph
polymorphes
kinase inhibitors
Prior art date
Application number
PE2014000191A
Other languages
English (en)
Inventor
Pingda Ren
Michael Martin
Original Assignee
Intellikine Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47669006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intellikine Llc filed Critical Intellikine Llc
Publication of PE20141358A1 publication Critical patent/PE20141358A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE LA FORMA C DE POLIMORFO DEL COMPUESTO DE FORMULA (I) QUE COMPRENDE: A) EXPONER UNA COMPOSICION QUE COMPRENDE UNO O MAS POLIMORFOS DE FORMA NO C DEL COMPUESTO DE FORMULA (I) A UN SISTEMA DE DISOLVENTES QUE ES UN SISTEMA DE CRISTALIZACION BINARIO QUE CONTIENE UN DISOLVENTE ORGANICO Y AGUA LIQUIDA DURANTE UN PERIODO DE TIEMPO SUFICIENTE PARA CONVERTIR 50% DE LA CANTIDAD TOTAL DE POLIMORFOS DE FORMA NO C EN LA FORMA C DEL COMPUESTO DE FORMULA (I); Y B) AISLAR DICHA FORMA C DE POLIMORFO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE LA FORMA A DE POLIMORFO DEL COMPUESTO DE FORMULA (I) Y A COMPOSICIONES FARMACEUTICAS DE DICHOS POLIMORFOS. DICHOS COMPUESTOS SON INHIBIDORES DE CINASAS TAL COMO mTor
PE2014000191A 2011-08-11 2012-08-10 Polimorfos de inhibidores de cinasas PE20141358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161522624P 2011-08-11 2011-08-11

Publications (1)

Publication Number Publication Date
PE20141358A1 true PE20141358A1 (es) 2014-10-12

Family

ID=47669006

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000191A PE20141358A1 (es) 2011-08-11 2012-08-10 Polimorfos de inhibidores de cinasas

Country Status (24)

Country Link
US (1) US20150065524A1 (es)
EP (1) EP2741749A4 (es)
JP (1) JP2014521726A (es)
KR (1) KR20140079368A (es)
CN (1) CN103957918A (es)
AU (1) AU2012294202B2 (es)
BR (1) BR112014003214A2 (es)
CA (1) CA2844742A1 (es)
CL (1) CL2014000343A1 (es)
CO (1) CO6960542A2 (es)
CR (1) CR20140082A (es)
DO (1) DOP2014000027A (es)
EA (1) EA027970B1 (es)
EC (1) ECSP14013236A (es)
HK (1) HK1199203A1 (es)
IL (1) IL230850A0 (es)
MX (1) MX2014001662A (es)
MY (1) MY186267A (es)
PE (1) PE20141358A1 (es)
RU (1) RU2636588C2 (es)
SG (2) SG2014009492A (es)
TN (1) TN2014000063A1 (es)
WO (1) WO2013023184A1 (es)
ZA (1) ZA201401211B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
BRPI0920121A2 (pt) 2008-10-15 2019-09-24 Angiochem Inc conjugados de etoposida e doxorubicina para liberação de fármaco
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
CN106994126A (zh) * 2011-11-08 2017-08-01 因特利凯有限责任公司 使用多种药剂的治疗方案
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途
EA201690987A1 (ru) 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
RU2714902C2 (ru) 2013-12-19 2020-02-20 Новартис Аг Химерные рецепторы антигена против мезотелина человека и их применение
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3119423B1 (en) 2014-03-15 2022-12-14 Novartis AG Treatment of cancer using chimeric antigen receptor
DK3888674T3 (da) 2014-04-07 2024-07-08 Novartis Ag Behandling af cancer ved anvendelse af anti-cd19-kimær antigenreceptor
EP3172234B1 (en) 2014-07-21 2020-04-08 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
KR20210149228A (ko) 2014-09-17 2021-12-08 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CN108473957B (zh) 2015-04-17 2024-07-16 诺华股份有限公司 改善嵌合抗原受体表达细胞的功效和扩增的方法
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
ES2636646B1 (es) * 2016-04-05 2018-08-03 Universidade De Santiago De Compostela NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
ES2837396T3 (es) 2016-11-23 2021-06-30 Bayer Cropscience Ag Derivados de 2-[3-(alquilsulfonil)-2H-indazol-2-il]-3H-imidazo[4,5-b]piridina y compuestos similares como pesticidas
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
ES2949908T3 (es) * 2018-01-09 2023-10-03 Halcyon Labs Private Ltd Proceso para la preparación de Crisaborol y sus intermedios
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
TWI659956B (zh) * 2011-01-10 2019-05-21 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式

Also Published As

Publication number Publication date
KR20140079368A (ko) 2014-06-26
EA027970B1 (ru) 2017-09-29
CO6960542A2 (es) 2014-05-30
ZA201401211B (en) 2015-12-23
NZ622208A (en) 2016-04-29
CA2844742A1 (en) 2013-02-14
AU2012294202B2 (en) 2017-02-23
MX2014001662A (es) 2014-08-26
SG2014009492A (en) 2014-09-26
WO2013023184A1 (en) 2013-02-14
ECSP14013236A (es) 2014-06-30
EP2741749A4 (en) 2015-04-15
EP2741749A1 (en) 2014-06-18
RU2636588C2 (ru) 2017-11-24
JP2014521726A (ja) 2014-08-28
MY186267A (en) 2021-07-01
SG10201606288TA (en) 2016-09-29
HK1199203A1 (en) 2015-06-26
BR112014003214A2 (pt) 2017-03-14
CN103957918A (zh) 2014-07-30
CL2014000343A1 (es) 2014-10-17
CR20140082A (es) 2014-06-03
DOP2014000027A (es) 2014-07-15
RU2014109023A (ru) 2015-09-20
EA201490446A1 (ru) 2014-05-30
AU2012294202A1 (en) 2014-03-06
TN2014000063A1 (en) 2015-07-01
US20150065524A1 (en) 2015-03-05
IL230850A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
PE20141358A1 (es) Polimorfos de inhibidores de cinasas
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
ECSP11011398A (es) Inhibidores de beta-secretasa
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CR20120268A (es) Método para reducir el estrés por temperatura de plantas
EA201170772A1 (ru) Органические соединения
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
NI201200017A (es) Formulación farmacéutica
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
EA201100037A1 (ru) Органические соединения
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
CR20130534A (es) Nuevos derivados de imidazol útiles para el tratamiento de artritis
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
CR20130177A (es) Método para reducir estrés hídrico en plantas
CL2018000241A1 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il) propanoico sustituido.
UA108378C2 (uk) Спосіб одержання плеуромутилінів
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
CU24366B1 (es) Compuestos que poseen un anillo que contiene nitrógeno salicílico unido a un grupo heteroarilo bicíclico útiles como inhibidores rorc2
EA201391371A1 (ru) Фармацевтическая композиция ситаглиптина
SA515360956B1 (ar) مشتق من 2-أسيل امينو ثيازول أو ملح من أملاحه

Legal Events

Date Code Title Description
FC Refusal